tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

NBIX Stock Latest News

Neurocrine price target lowered to $155 from $163 at Guggenheim
The FlyNeurocrine price target lowered to $155 from $163 at Guggenheim
54m ago
NBIX
Neurocrine Biosciences Appoints Dr. Keswani as CMO
PremiumCompany Announcements
Neurocrine Biosciences Appoints Dr. Keswani as CMO
6d ago
8K
NBIX
Neurocrine names Dr. Sanjay Keswani as Chief Medical Officer
PremiumThe Fly
Neurocrine names Dr. Sanjay Keswani as Chief Medical Officer
6d ago
NBIX
Neurocrine price target lowered to $137 from $154 at UBS
PremiumThe Fly
Neurocrine price target lowered to $137 from $154 at UBS
6d ago
NBIX
Neurocrine’s Strong Market Position and Growth Potential Justify Buy Rating Amid Challenges
PremiumRatings
Neurocrine’s Strong Market Position and Growth Potential Justify Buy Rating Amid Challenges
6d ago
NBIX
Neurocrine price target raised to $184 from $183 at JPMorgan
PremiumThe FlyNeurocrine price target raised to $184 from $183 at JPMorgan
15d ago
NBIX
Neurocrine’s ingrezza shows efficacy in tardive dyskinesia study
Premium
The Fly
Neurocrine’s ingrezza shows efficacy in tardive dyskinesia study
21d ago
NBIX
Neurocrine presents new KINECT-HD data
Premium
The Fly
Neurocrine presents new KINECT-HD data
24d ago
NBIX
Neurocrine price target lowered to $139 from $148 at RBC Capital
PremiumThe Fly
Neurocrine price target lowered to $139 from $148 at RBC Capital
30d ago
NBIX
DA Davidson technology analysts hold an analyst/industry conference call
PremiumThe Fly
DA Davidson technology analysts hold an analyst/industry conference call
1M ago
EA
CXT
Neurocrine assumed with an Overweight at Morgan Stanley
PremiumThe Fly
Neurocrine assumed with an Overweight at Morgan Stanley
1M ago
NBIX
Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections
PremiumRatings
Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections
1M ago
NBIX
Neurocrine begins Phase 1 clinical study of NBI-1140675
PremiumThe FlyNeurocrine begins Phase 1 clinical study of NBI-1140675
1M ago
NBIX
Positive Market Outlook for Neurocrine’s Crenessity Driven by Unmet Needs and Strong Physician Adoption
Premium
Ratings
Positive Market Outlook for Neurocrine’s Crenessity Driven by Unmet Needs and Strong Physician Adoption
1M ago
NBIX
Neurocrine reports patient-reported outcome data from KINECT-PRO study
Premium
The Fly
Neurocrine reports patient-reported outcome data from KINECT-PRO study
1M ago
NBIX
Neurocrine price target lowered to $183 from $191 at JPMorgan
PremiumThe Fly
Neurocrine price target lowered to $183 from $191 at JPMorgan
1M ago
NBIX
Neurocrine board of directors authorizes $500M share repurchase program
PremiumThe Fly
Neurocrine board of directors authorizes $500M share repurchase program
2M ago
NBIX
Promising Market Potential and Therapeutic Advancements Drive Buy Rating for Neurocrine’s Crenessity
PremiumRatings
Promising Market Potential and Therapeutic Advancements Drive Buy Rating for Neurocrine’s Crenessity
2M ago
NBIX
Buy Rating on Neurocrine Due to Stabilization Prospects and Competitive Landscape Opportunities
PremiumRatings
Buy Rating on Neurocrine Due to Stabilization Prospects and Competitive Landscape Opportunities
2M ago
NBIX
Neurocrine Biosciences Faces Market Adoption Challenges with CRENESSITY Launch
PremiumCompany AnnouncementsNeurocrine Biosciences Faces Market Adoption Challenges with CRENESSITY Launch
2M ago
NBIX
Neurocrine’s Potential Upside: Buy Rating Amid Market Overreaction and Pipeline Prospects
Premium
Ratings
Neurocrine’s Potential Upside: Buy Rating Amid Market Overreaction and Pipeline Prospects
2M ago
NBIX
Neurocrine initiated with a Hold at Deutsche Bank
Premium
The Fly
Neurocrine initiated with a Hold at Deutsche Bank
2M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >